Acquired Cystic Kidney Disease Medication

Updated: Mar 13, 2020
  • Author: Manish Suneja, MD, FASN, FACP; Chief Editor: Vecihi Batuman, MD, FASN  more...
  • Print

Medication Summary

No specific drugs are indicated in the management of acquired cystic kidney disease, except analgesics for the treatment of pain. Drugs for underlying disease are required.



Class Summary

These agents act at the central nervous system (CNS) mu receptors and are the criterion standards for the treatment of pain resulting from kidney disease. They are inexpensive and proven effective. Disadvantages include sedation, respiratory depression, smooth muscle spasm, and the potential for abuse and addiction.

A review of opioid equivalents and conversions may be found in the following reference article:


Acetaminophen (Tylenol, Aspirin Free Anacin, Feverall, Acephen, Cetafen Extra, FeverAll, Little Fevers, Mapap, Non-Aspirin Pain Reliever, Nortemp Children's, Ofimev, Pain Eze, Pharbetol, Q-Pap, Silapap, Triamininc, Valorin)

Drug of choice (DOC) for pain in patients with documented hypersensitivity to aspirin or NSAIDs, with upper GI disease, or who are taking oral anticoagulants.

Effective in relieving mild to moderate acute pain; however, has no peripheral anti-inflammatory effects. May be preferred in elderly patients because of fewer GI and renal adverse effects.


Indicated for moderate to severe pain. Binds to opiate receptors in CNS, causing inhibition of ascending pain pathways, altering perception and response to pain.

Morphine (MS Contin, Duramorph, Avinza, Astramorph, Depodur, Infumorph, Kadian, MorphaBond, Arymo ER)

DOC for analgesia because of reliable and predictable effects, safety profile, and ease of reversibility with naloxone. Various IV doses are used; commonly titrated until desired effect obtained.

For chronic severe pain unremitting to alternative therapy, oral immediate–release and extended-release morphine sulfate may be warranted. Arymo ER is a morphine sulfate abuse-deterrent formulation.